Climb Bio (NASDAQ:CLYM) Now Covered by Analysts at William Blair

William Blair began coverage on shares of Climb Bio (NASDAQ:CLYM) in a research report report published on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating on the stock.

A number of other brokerages have also commented on CLYM. Wall Street Zen raised Climb Bio from a “sell” rating to a “hold” rating in a report on Monday, October 6th. BTIG Research upped their price objective on Climb Bio from $7.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. Baird R W raised Climb Bio to a “strong-buy” rating in a report on Friday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. Finally, Robert W. Baird began coverage on Climb Bio in a report on Friday, August 15th. They issued an “outperform” rating and a $9.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $9.20.

Climb Bio Trading Up 0.5%

CLYM stock opened at $1.95 on Thursday. The firm has a market capitalization of $132.13 million, a PE ratio of -2.79 and a beta of -0.07. Climb Bio has a 1-year low of $1.05 and a 1-year high of $5.10. The business’s 50 day simple moving average is $2.09 and its 200 day simple moving average is $1.57.

Climb Bio (NASDAQ:CLYM) last posted its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. As a group, sell-side analysts predict that Climb Bio will post -1.57 EPS for the current fiscal year.

Institutional Trading of Climb Bio

A number of institutional investors have recently modified their holdings of the stock. Shay Capital LLC lifted its position in shares of Climb Bio by 107.5% during the 2nd quarter. Shay Capital LLC now owns 415,000 shares of the company’s stock valued at $515,000 after acquiring an additional 215,000 shares during the period. Jane Street Group LLC bought a new stake in shares of Climb Bio during the 2nd quarter valued at $184,000. Diadema Partners LP lifted its position in shares of Climb Bio by 4.8% during the 2nd quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock valued at $871,000 after acquiring an additional 32,332 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Climb Bio during the 2nd quarter valued at $43,000. Finally, Marshall Wace LLP bought a new stake in shares of Climb Bio during the 2nd quarter valued at $46,000. 69.76% of the stock is currently owned by institutional investors.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.